FMT has been shown to reprogram the gut microbiota and the TME among immunotherapy-refractory patients (68, 90) and to restore anti-PD-1 sensitivity among patients with refractory melanoma and other malignancies (91–94). The gene discussed is PDCD1; the disease is melanoma.